MARK4 inhibitor 1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

MARK4 inhibitor 1  纯度: 98.29%

MARK4 inhibitor 1 是有效的 MARK4 的抑制剂，IC50 值为1.54 μM。MARK4 inhibitor 1抑制癌细胞增殖、转移，诱导凋亡。

MARK4 inhibitor 1

MARK4 inhibitor 1 Chemical Structure

CAS No. : 2271081-58-2

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥3190 In-stock
5 mg ￥2900 In-stock
10 mg ￥4300 In-stock
25 mg ￥7800 In-stock
50 mg ￥11000 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

MARK4 inhibitor 1 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Epigenetics Compound Library
  • Kinase Inhibitor Library
  • PI3K/Akt/mTOR Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Antioxidants Compound Library
  • Oxygen Sensing Compound Library
  • Glycolysis Compound Library
  • Cytoskeleton Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Lipid Metabolism Compound Library
  • Glucose Metabolism Compound Library
  • Targeted Diversity Library

生物活性

MARK4 inhibitor 1 is a potent microtubule affinity-regulating kinase 4 (MARK4) inhibitor, with an IC50 of 1.54 μM. MARK4 inhibitor 1 inhibits cancer cell proliferation, metastasis and induces apoptosis[1].

IC50 & Target

IC50: 1.54 μM (MARK4)[1].
分子量

390.40

Formula

C20H18N6O3
CAS 号

2271081-58-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 5 mg/mL (12.81 mM; ultrasonic and adjust pH to 2 with HCl)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.5615 mL 12.8074 mL 25.6148 mL
5 mM 0.5123 mL 2.5615 mL 5.1230 mL
10 mM 0.2561 mL 1.2807 mL 2.5615 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Aneja B, et al. Design and development of Isatin-triazole hydrazones as potential inhibitors of microtubule affinity-regulating kinase 4 for the therapeutic management of cell proliferation and metastasis. Eur J Med Chem. 2019 Feb 1;163:840-852.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务